Anika Therapeutics (ANIK) Revenue (2010 - 2026)

Anika Therapeutics (ANIK) has reported Revenue for 17 consecutive years, with $32.6 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Revenue rose 15.56% year-over-year to $32.6 million in Q2 2026; TTM through Jun 2026 was $120.7 million, a 5.33% increase from a year earlier, with the FY2025 full-year figure at $112.8 million, down 5.91% from the prior year.
• Revenue was $32.6 million for Q2 2026 at Anika Therapeutics, up from $29.6 million in the prior quarter.
• Over five years, Revenue peaked at $44.3 million in Q2 2023 and troughed at -$2.9 million in Q4 2023.
• A 5-year average of $29.4 million and a median of $30.6 million in 2024 frame the typical range for Revenue.
• Across the five-year window, Revenue sank 107.78% in 2022 and surged 1155.61% in 2024, its largest moves.
• Over 5 years, Revenue stood at -$2.8 million in 2022, then fell by 4.02% to -$2.9 million in 2023, then surged by 1155.61% to $30.6 million in 2024, then rose by 0.04% to $30.6 million in 2025, then gained by 6.52% to $32.6 million in 2026.
• The last three Revenue figures came in at $32.6 million (Q2 2026), $29.6 million (Q1 2026), and $30.6 million (Q4 2025), per Business Quant data.